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Objective: To evaluate the effect of red blood cell (RBC) antibody screening in the 27th week of 31 
pregnancy in Rhc-negative women, on detection of alloimmunisation, undetected at first 32 
trimester screening (‘late’ alloimmunisation), and subsequent Haemolytic Disease of the Fetus 33 
and Newborn (HDFN);to assess risk factors for late alloimmunisation.  34 
Design: Prospective cohort and nested case-control study. 35 
Setting: The Netherlands. 36 
Population: Two-year nationwide cohort.  37 
Methods: Prospectively inclusion of Rhc-negative women with negative first trimester screening 38 
and of screen-negative controls. 39 
Main outcomes measures: Late alloimmunisation, HDFN.  40 
Analysis: Assessment of incidence and Numbers Needed to Screen (NNS) of late 41 
alloimmunisation and HDFN; logistic regression analysis to establish risk factors for late 42 
alloimmunisation. 43 
Results: Late alloimmunisation occurred in 99/62,096 (0.159%) of Rhc-negative women, 90% 44 
had c-/E-antibodies, 10% non-Rhesus-antibodies. Severe HDFN (foetal/neonatal transfusion) 45 
occurred in 2/62,096 (0.003%) of Rhc-negative women and 2% of late alloimmunisations; 46 
moderate HDFN (phototherapy) occurred in 20 children (22.5%;95%-CI:13.8-31.1%). Perinatal 47 
survival was 100%. The NNS to detect one HDFN case was 2,823 (31,048 for severe, 3,105 for 48 
moderate HDFN). Significant risk factors were former blood transfusion OR 10.4;95%-CI:1.14-49 
94.9), parity (P-1 OR 11.8;95%-CI:3.00-46.5;P:>1 OR 7.77;95%-CI:1.70-35.4) and 50 
amniocentesis/chorionic villus sampling during current pregnancy (OR 9.20;95%-CI:1.16-72.9). 51 
Conclusion: Additional screening of Rhc-negative women improved detection of late 52 
alloimmunisation and HDFN, facilitating timely treatment, with a NNS of 2,823. Independent risk 53 
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factors for late alloimmunisation were blood transfusion, parity and chorionic villus 54 
sampling/amniocentesis in the current pregnancy. The occurrence of most factors before the 55 
current pregnancy suggests a secondary immune response explaining most late 56 
alloimmunisations.  57 
Tweetable abstract: 3rd trimester screening for alloimmunisation in Rhc−neg women improves 58 
detection and treatment of severe HDFN. 59 






Haemolytic Disease of the Fetus and Newborn (HDFN) is caused by maternal alloimmunisation 64 
against paternally inherited fetal red blood cell (RBC) antigens. HDFN may lead to fetal anaemia, 65 
hydrops, asphyxia, perinatal death, and neonatal hyperbilirubinaemia, that may cause 66 
‘kernicterus’. Kernicterus can result in neurodevelopmental impairment with athetoid cerebral 67 
palsy, hearing problems and psychomotor handicaps.1-7 Most severe HDFN cases are caused by  68 
RhD-, Rhc- and Kell-antibodies (hereafter called anti-D, anti-c, etcetera).1-5, 8 Timely detection of 69 
maternal alloimmunisation facilitates fetal monitoring, aimed to identify fetuses with severe 70 
disease needing intrauterine transfusions (IUT) and/or preterm delivery followed by 71 
phototherapy or (exchange) transfusions. These therapies have all contributed to a considerable 72 
decrease in HDFN-related perinatal death and long-term sequelae. 9, 10 73 
Most Western countries have maternal alloimmunisation screening programmes. A wide 74 
variation in design of these programmes exists between and within countries, ranging from 75 
several screenings in all pregnant women to a single screening of RhD-negative women only.1, 11-76 
15 77 
In the Netherlands, all pregnant women are screened for RBC antibodies at the booking visit; 78 
screening is repeated in week 27 for RhD-negative women, and since July 2011 also for Rhc-79 
negative women. 16, 17 Implementation of screening in Rhc-negative women, comprising 18.7% 80 
of pregnancies18, was based on a nationwide study in 400,000 pregnancies, showing that 25% of 81 
severe HDFN cases in RhD-positive women occurred unexpectedly, after a negative screening 82 
result in the first trimester. Some of these unexpected cases suffered from HDFN-related 83 
handicaps due to perinatal asphyxia or kernicterus, because fetal anaemia and 84 
hyperbilirubinaemia were not timely detected. In contrast, all cases of alloimmunisation 85 
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detected at first trimester screening were timely treated and children were healthy at the age of 86 
one year.8 All first trimester screen-negative cases of severe HDFN were caused by anti-c and/or 87 
anti-E. However, long-term sequelae were only found in anti-c cases. 8 Based on this outcome an 88 
additional screening of all Rhc-negative women in week 27 was set-up to increase the detection 89 
rate of severe HDFN cases with 25% (from 75 to 100%). Undetected, these cases might result in 90 
severe anaemia, hydrops, death or (too) late treatment of icterus.  91 
So far, a few smaller studies showed no advantage of a second screening in RhD-positive 92 
women.19-23 In the current large nationwide study, we set out to assess the incidence of HDFN 93 
after a positive antibody screening in week 27 in Rhc-negative pregnant women and evaluated 94 
whether implementation of this third trimester screening improved timely diagnosis and 95 
treatment of HDFN. In addition, we aimed to identify risk factors for alloimmunisation first 96 
recognized late in pregnancy, in order to provide insight in the causative mechanism in order to 97 
be able to develop strategies for the prevention and timely detection of late alloimmunisation.  98 
Methods 99 
Setting and Prevention programme in the Netherlands 100 
In the Netherlands, all pregnant women are typed for ABO, RhD and Rhc blood group antigens 101 
and screened for RBC antibodies at the first trimester booking visit. All RhD- and Rhc-negative 102 
women, without RBC antibodies at the initial screening, are screened again in week 27.17 This 103 
repeated screening is centralised in the laboratory of Sanquin Diagnostics in Amsterdam. When 104 
clinically relevant RBC antibodies are detected, i.e. antibodies with the potency to destroy fetal 105 
RBC’s, the antibody titre and the Antibody Dependent Cellular Cytotoxicity Test (ADCC) are 106 
performed, in order to assess the ability of these antibodies to cause fetal haemolysis. The 107 
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father of the fetus is typed for cognate antigen(s) and in case of heterozygosity, non-invasive 108 
typing on fetal DNA in maternal plasma is offered (for RHD, RHC, RHc, RHE and K).24 If the fetus 109 
does not have the cognate antigen(s), further monitoring of the pregnancy is not necessary. If 110 
the fetus is diagnosed as antigen-positive, the pregnancy is frequently monitored by laboratory 111 
testing. In the presence of non-RhD RBC antibodies, an antibody titre ≥ 1:16 and/or ADCC test 112 
≥30% indicates a major risk for HDFN, and fetal anaemia is monitored with middle cerebral 113 
artery (MCA) Doppler measurements.25, 26 Severe fetal anaemia is treated with intrauterine 114 
transfusion(s) (IUT’s) at the Leiden University Medical Centre (LUMC), which is the national 115 
Dutch referral centre for management and treatment of pregnancies complicated by maternal 116 
red cell alloimmunisation. In the Netherlands this study design does not require formal approval 117 
of the Medical Ethical Committee. 118 
Study design 119 
To assess the occurrence of HDFN in Rhc-negative women diagnosed with newly detected RBC 120 
antibodies (cases) at week 27 of pregnancy (‘late alloimmunisation’), we prospectively collected 121 
data on all these women and their offspring in the Netherlands between October 1st 2011 and 122 
October 1st 2013.  123 
 124 
The association between potential risk factors for late alloimmunisation and the occurrence of 125 
late alloimmunisation among Rhc-negative pregnant women was examined in a case-control 126 
study comprising Rhc-negative women with (the cases) and without (the controls) late 127 
alloimmunisation, sampled between October 1st 2011 and October 1st 2012. Our planned study 128 
period was one year. To obtain a more reliable estimation of the incidence of severe HDFN we 129 
extended the study period with one year. We did not prolong the case-control study. 130 
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Cases and controls were identified at Sanquin Diagnostics Amsterdam. For each case, three 131 
controls were selected. These were the first three Rhc-negative women that were screened 132 
negative, directly following the alloimmunised Rhc-negative woman.  133 
Outcomes  134 
The primary outcome was the incidence of severe and moderate HDFN in the offspring of Rhc-135 
negative pregnant women with antibodies first detected at 27 weeks gestation. Severe HDFN 136 
was defined as alloimmune disease with the need for intrauterine transfusion and/or neonatal 137 
exchange or blood transfusions in the first week of life. Moderate HDFN was defined as the need 138 
for treatment of neonatal jaundice with phototherapy only. Long-term sequelae are all long 139 
term impairments, most likely associated with the severe HDFN, such as kernicterus and/or 140 
perinatal asphyxia. 141 
Potential risk factors 142 
We hypothesized that late in pregnancy detected alloimmunisations may emerge from a 143 
primary immune response during the current pregnancy or from a secondary immune response, 144 
triggered by fetomaternal (micro-)transfusions (FMT) of antigen-positive RBCs.12, 20 Data on 145 
known risk factors for red cell alloimmunisation, including risk factors for FMT during the 146 
current pregnancy were collected in cases and controls. 147 
Data collection 148 
For inclusion of cases and controls, two of the researchers (YS, JK) contacted the obstetric care 149 
provider (midwife, general practitioner and/or obstetrician) to explain our study. The obstetric 150 
care provider asked the pregnant woman for consent for data collection and collection of cord 151 
blood, to be sent to our laboratory by post. 152 
8 
 
During the first year of the study, data on potential risk factors were collected during pregnancy, 153 
immediately after consent was given, from the obstetric care provider and/or from the pregnant 154 
woman. Potential risk factors comprised both general risk factors and in-pregnancy risk factors. 155 
General risk factors included factors of general history (RBC transfusions, surgery, 156 
haematological diseases), as well as gravidity and parity. ‘In-pregnancy risk factors’ were factors 157 
within the previous pregnancy (gender child, caesarean section, surgical removal of placenta 158 
and postpartum haemorrhage (>1L), and factors during the current pregnancy until week 27 159 
(vaginal bleeding, abdominal trauma and invasive diagnostic and therapeutic interventions). 27-30 160 
To assess the occurrence of mild or severe HDFN in the study group, we collected the results of 161 
laboratory monitoring during pregnancy from Sanquin Diagnostics, data of clinical monitoring 162 
and IUT treatment during pregnancy, if applicable, from the LUMC, and neonatal outcome data 163 
about treatment with blood transfusion(s) or phototherapy from the obstetric care provider, 164 
from the paediatrician, from hospital laboratories and/or from the mothers, within two months 165 
after birth. 166 
All data were collected by questionnaires, which were completed by phone, e-mail or by post.  167 
 168 
Data analyses 169 
We assessed the incidence of late alloimmunisation as proportion of all screened Rhc-negative 170 
women at 27 week of gestation and the occurrence of severe and moderate HDFN in association 171 
with late immunisation. The cases with HDFN were classified by antibody specificity.  When 172 
multiple antibodies were present, the antibody specificity for which the paternal antigen was 173 
positive and/or with the highest estimated risk for development of HDFN was considered as 174 
‘dominant’ antibody. 175 
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We calculated the Number Needed to Screen (NNS) to detect one case with severe HDFN timely, 176 
assuming that none of these cases would have been detected without the third trimester 177 
screening programme in Rhc-negative women. We also calculated the NNS to detect one case 178 
with moderate HDFN and to detect one case of ‘late alloimmunisation’. The NNS were 179 
calculated as 1/(0-incidence of severe/moderate HDFN/late alloimmunisation in Rhc-negative 180 
women, screened in the third trimester).  181 
Dichotomous outcomes were described as number and percentage, normally distributed  182 
continuous variables as mean and standard deviation and not-normally distributed continuous 183 
variables as median and range.  184 
The association between potential risk factors and the occurrence of late alloimmunisation was 185 
examined with logistic regression, firstly by univariate and secondly by multivariate analysis.  186 
Potential ‘general’ risk factors and in-pregnancy risk factors during the current pregnancy were 187 
included in the first logistic model. Potential in-pregnancy risk factors originating from the 188 
previous pregnancy were included in a second logistic model. Interactions between the 189 
covariates were tested formally. All statistical analyses were performed with the Statistical 190 
Package for the Social Sciences (SPSS) 21.0. 191 
RESULTS 192 
Study population and response 193 
From October 1st 2011 till October 1st 2013, 62,096 Rhc-negative women, without RBC 194 
antibodies in the first trimester of pregnancy, were screened again in week 27 of gestation. Of 195 
these, 99 (0.16%;95-CI 0.13-0.19% ) had newly detected clinically relevant RBC antibodies 196 
(Figure 1). During the first year of the study, 168 controls were selected (matched to 54 cases), 197 
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of which 104 (62%) gave consent to collect data. The proportions of nulliparae, primiparae and 198 
multiparae in the control group were 47.1% (95%-CI 34.1-60.1%), 35.6% (95%-CI 24.3–46.9%) 199 
 and 18.5% (95%-CI: 2.7–34.3%) respectively, compared to proportions of 44.9%, 35.9% and 200 
19.2% respectively in the Netherlands in 2012.31  201 
From the newly immunised pregnant women, 10% (10/99) refused participation in the study. 202 
None of these  women had either titres or ADCC values above the cut-off to select high-risk 203 
cases, or was referred to the LUMC, the national referral centre for severe alloimmunised 204 
pregnancies. Therefore, the occurrence of severe fetal haemolytic disease in the non-consent 205 
group is very unlikely, although severe neonatal HDFN cannot be completely ruled out. 206 
Therefore, incidences for severe HDFN are described in the whole group, but for moderate 207 
HDFN only in the group with consent. 208 
 209 
Incidence of late alloimmunisation 210 
From the 99 late alloimmunisations, anti-c was the most frequently detected alloantibody 211 
(65/99;66%), in 20 cases anti-c was present in combination with anti-E and in seven cases with 212 
other antibodies. Anti-E was present in 45/99 (45%) cases, in 25 as a single antibody specificity. 213 
In 54 cases with anti-c and 36 with anti-E the father was tested for the cognate antigen(s) and 214 
was found to be positive in 53 and 35 cases, respectively. For the remaining 17 antibody 215 
specificities, the father was typed in 14 cases and appeared positive for the cognate antigen(s) 216 
in 5 cases (Table 1). The NNS to detect one late alloimmunisation was 628 (Table 2). 217 
Incidence of HDFN  218 
Severe HDFN due to RBC antibodies first detected at 27 weeks, occurred in two of the 62,096 219 
Rhc-negative pregnancies screened and 2.0% of screen positive pregnancies (Table 2). One 220 
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severe case was caused by the combination of anti-c and anti-E, mostly by anti-E (titre 1:256). 221 
During this pregnancy, one IUT (pre-transfusion Hb 9.0 g/dL) was performed at 30+3 weeks, 222 
followed by induction of labour at 36 weeks. The Hb and Ht levels postpartum were 12.4 (g/dL) 223 
and 0.42, respectively. Phototherapy was given during seven days. An exchange transfusion was 224 
needed after two operations for pyloric stenosis, carried out after the first week of life. Two 225 
months postpartum this child was confirmed to be in a good condition. The other severe case 226 
was caused by anti-c only. No intrauterine transfusion was given. Labour was induced at 36 227 
weeks + 4 days; Hb and Ht at birth were 13.3 (g/dL) and 0.42, respectively. The lowest Hb was 228 
9.8 (g/dL), five top-up transfusions were given, no exchange transfusions were needed. 229 
Phototherapy was given in 20 cases (12 anti-c, 5 anti-E and 3 anti-c and anti-E), resulting in an 230 
incidence of moderate HDFN of 0.032% of all screened Rhc-negative women (Table 2) and 231 
20.20% of screen-positive pregnancies. In cases with known outcome (n=89) the incidence of 232 
moderate HDFN was 22.5%(95%-CI:13.8-31.1%).  233 
The NNS to detect one case of severe HDFN was 31,048 and to detect one case of moderate 234 
HDFN 3,105. 235 
Six cases of moderate HDFN occurred in association with laboratory test results below the 236 
aforementioned cut-offs.  237 
Forty-nine children of the 90 pregnancies with anti-c and/or anti-E, were antigen-positive for the 238 
cognate antigens (based on antigen typing of the child (n=26) or homozygosity of the father for 239 
the antigens concerned (n=23)), five were antigen-negative and in 36 cases the antigen-typing 240 
was unknown. We calculated that 17 children with unknown antigen-typing should have been 241 
antigen-positive (Box S1), resulting in a risk for moderate HDFN in antigen-positive 242 
fetuses/children from c-/E-immunised pregnancies of 30.35% (20/66;95%-CI 24.6-36.0%). 243 
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Interventions for maternal alloimmunisation 244 
Preterm induction of labour was performed in both severe cases. In addition, 13 term inductions 245 
were performed at least in part based on the presence of RBC antibodies (Figure S1), without 246 
signs of fetal anaemia on ultrasound or Doppler. Five of the six cases with antibody titres and/or 247 
ADCC test results above the cut-off values used in the Netherlands to indicate high-risk cases 248 
needed phototherapy treatment. None of the seven cases of induced labour, with laboratory 249 
testing results below the cut-offs, needed treatment for HDFN. Two of the phototherapy cases 250 
were born prematurely (gestational age 28 and 34 weeks respectively), which was not 251 
associated with the maternal alloimmunisation. Twenty-four children were admitted to the 252 
neonatal ward, of which 20 were treated with phototherapy only. This concerned almost one 253 
third of anti-c cases, 14% of only anti-E cases, and none of the cases with other antibodies.  254 
Risk Factors for late alloimmunisation 255 
A history of RBC transfusion, major surgery, previous parity, maternal age were, as well as 256 
amniocentesis/chorion villus sampling in the current pregnancy were univariately associated 257 
with the occurrence of late alloimmunisation in Rhc-negative women (Table S1).  258 
Potential risk factors within previous pregnancies were not associated with late 259 
alloimmunisation. 260 
RBC transfusion, parity and amniocentesis/chorion villus sampling in the current pregnancy 261 




Main findings 264 
Late alloimmunisation, detected at 27th week screening, occurred in 0.16% of all pregnancies of 265 
Rhc-negative women. Within the group of late alloimmunisation, the risk for severe HDFN was 266 
2% and for moderate HDFN 22.5%.  Most new immunisations and all HDFN cases were caused 267 
by anti-c and/or anti-E. Amniocentesis or chorionic villus sampling in the current pregnancy, as 268 
well as parity and a history of RBC transfusion were independent risk factors for 269 
alloimmunisation detected late in pregnancy. 270 
Strengths and limitations 271 
To our knowledge this is the first prospective nationwide study on the effect of a second 272 
antibody screening in Rhc-negative women. Our study provides a reliable estimation of the 273 
incidence of late alloimmunisation and subsequent HDFN. Although outcome data of 10% of the 274 
cases were missing, severe HDFN is very unlikely in these cases, because laboratory results were 275 
not above the cut-off values indicating high-risk for HDFN and no cases needed monitoring in 276 
the national referral centre. Moreover, in some cases it was impossible to separate the 277 
contribution of alloimmunisation from other causes for hyperbilirubinaemia, for example in two 278 
prematurely born children. This may have caused an –at most slight- overestimation of the 279 
incidence of moderate HDFN.  280 
 281 
One third of the controls did not participate in our study, which may have caused selection bias 282 
in our risk factor analysis. Most common reasons for non-participating were a language barrier, 283 
social problems and declined cooperation of the obstetric caregiver, reasons unlikely associated 284 
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with risk factors for alloimmunisation. This was supported by the distribution of parity, a strong 285 
risk factor, in our control group, which did not differ from national data.  286 
Some risk factors showed wide confidence intervals, due mainly to limited numbers. We 287 
consider it unlikely that with increased numbers and thus narrowed confidence intervals, 288 
the risk estimations would turn out different. 289 
Previous findings and interpretation  290 
The incidence of late alloimmunisation in Rhc-negative women was in line with expectations 291 
following our former evaluation of the Dutch screening programme for non-RhD antibodies.8 No 292 
studies are available yet in which only Rhc-negative women were screened for late 293 
alloimmunisation. A small Dutch study in which RhD-positive women underwent a second 294 
screening reported higher incidences of late alloimmunisation, which might at least partly be 295 
explained by the fact that this study was performed in a population of parous women, at 296 
increased risk for alloimmunisation.32 Studies including 3,000-70,000 RhD-positive pregnant 297 
women reported incidences of late alloimmunisation varying between 0.06 and 0.43%, in line 298 
with our data.33 The incidence of late alloimmunisation in Rhc-negative women might be 299 
somewhat higher than in all RhD-positive women, since anti-c and anti-E, the most frequent 300 
newly detected antibodies in all studies, are found especially in Rhc-negative women. 301 
Remarkably, the incidence of severe HDFN in cases with late alloimmunisation was considerably 302 
lower than expected, resulting in a NNS to detect one severe HDFN case of 31,048. Based on the 303 
0.002% incidence of severe HDFN by late alloimmunisation, found in our study in 2003-2004,8 a 304 
NNS of about 9,000 was expected. An explanation for this decreased incidence might be that 305 
timely detection of cases at risk for fetal haemolysis, followed by labour induction in week 37, as 306 
advised in the Dutch Guideline on maternal alloimmunisation, preventing the development to 307 
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severe HDFN in some cases.34 This explanation is supported by the shorter median gestational 308 
age in cases with labour induction, followed by phototherapy treatment, than in the missed 309 
severe HDFN cases in our former study (265 versus 274 days). Moreover, the increased 310 
availability of intensive phototherapy combined with the introduction of a new guideline in 2008 311 
including a more conservative approach concerning the use of exchange transfusions to lower 312 
bilirubin levels, will have reduced the use of exchange transfusions.  313 
Both severe cases of HDFN in our study, were  probably not detected without the screening 314 
programme. These were uncomplicated pregnancies and normally developed fetuses. Current 315 
standard of care for such pregnancies in The Netherlands does not include routine ultrasound in 316 
the third trimester. Even if ultrasound would be done, without a high index of suspicion specific 317 
anaemia detection by middle cerebral artery Doppler would not have taken place. Clinically, 318 
only reduced fetal movements and hydrops on ultrasound would be detected, which are very 319 
late stages of disease associated with a significant perinatal death risk. Therefore, we 320 
hypothesize that the remarkable decrease of the incidence of severe HDFN by late 321 
alloimmunisation, for which no other explanation can be given, is a benefit of the 322 
implementation of third trimester screening in Rhc-negative women, a benefit that highly 323 
exceeds the benefit as suggested by the NNS of 31,048.  324 
 325 
A possible negative feature of screening might be a number of relatively early inductions of 326 
labour because of maternal alloimmunisation, despite laboratory test results being below the 327 
cut-offs, as was the case in 50% of term inductions. It should be kept in mind that in these cases, 328 
factors other than maternal alloimmunisation may have contributed to the decision to induce 329 
labour. It was however reassuring that the induction rate in cases was comparable with national 330 




One severe HDFN case occurred in a pregnancy complicated by low anti-c and high anti-E levels, 333 
while three moderate cases were due to anti-E only. This raises the question whether also 334 
women with an Rhc-positive but RhE-negative phenotype (CcDee (35%) or ccDee (1,6%)20 should 335 
be offered a second screening. Our former evaluation showed only one missed case during two 336 
years with the CcDee phenotype, while all cases with long term sequelae were caused by anti-c.8 337 
Therefore, expanding the screening to all RhE-negative women will most likely not significantly 338 
improve the detection of severe HDFN cases. Registration of screen-undetected cases with 339 
HDFN would be helpful to clarify this issue. 340 
 341 
We identified risk factors before as well as during the current pregnancy. Parity and blood 342 
transfusion were identified in our former study as risk factors for early alloimmunisation.21 343 
These findings are in accordance with the hypothesis that the primary immune response 344 
occurred already in, or following, a previous pregnancy. Antibody levels then fall too low to be 345 
detected at first trimester screening, and rise again after renewed contact during pregnancy of 346 
the maternal immune system with fetal red cells. This might have occurred after amniocentesis 347 
or chorionic villus sampling, when these cases also had one or more risk factors before the 348 
current pregnancy. The contribution of each of the risk factors is difficult to be estimated in this 349 
relatively small study. In the risk factor analysis only cases from the first year of the study with 350 
consent to collect data on risk factors (n=46) were included. We did not match for potential 351 
confounders, because, as described by Altman (1991), any variable used for matching cannot be 352 
investigated as a possible risk factor for maternal alloimmunisation.35 As this is the first study on 353 
risk factors for late alloimmunisation, we aimed to investigate all possible risk factors instead of 354 
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collecting variables, known as risk factors for maternal alloimmunization  detected at first 355 
trimester screening only. 356 
Our analysis underlines a restrictive blood transfusion policy, as well as the use of Rhc- and RhE-357 
matched donor blood, according to current Dutch guidelines.36 Moreover, invasive diagnostic 358 
procedures are associated with fetomaternal haemorhage 29, which can cause a primary or 359 
secondary immune response, the latter with a rapid rise of maternal RBC antibody levels. This 360 
underlines the importance of non-invasive prenatal testing (NIPT).37 361 
Theoretically, third trimester screening in Rhc-negative women may be restricted to women 362 
with risk factors, 62% of the pregnant women in our control group. However, subgroup first 363 
trimester screening, as advised by the Dutch Health Council16, was not implemented, because of 364 
practical objections of the obstetric care workers. Our study confirms the usefulness of the 365 
additional third trimester screening for RBC alloantibodies in all Rhc-negative women.  366 
Our previously published economic analysis showed that the extra costs of the expanded 367 
screening programme in the Netherlands are about 1.4 M€/year. As we detected two severe 368 
cases during two years, this means 1.4 M€/case, which is lower than the estimated life time 369 
costs of a surviving child with long term sequelae, which are about 3 M euro, when this person 370 
reaches the age of 60 years.38 We also showed that the psychological burden of antibody 371 
screening is small and balanced with the benefits.39  372 
Conclusion 373 
A repeated RBC antibody screening in week 27 of pregnancy in Rhc-negative women contributes 374 
to the timely detection and treatment of severe HDFN and most likely also leads to a decrease 375 
of the incidence of severe HDFN. An optimal management eventually results in less severely 376 
compromised cases and a reduction in the long-term morbidity and mortality associated with 377 
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Figure 1: Flowchart of inclusions and exclusions of cases and controls.  
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Table 1. Newly detected clinically relevant RBC antibodies in week 27 in Rhc-negative pregnant women 
Antibody specificity N (%) Phenotype father antigen
dominant antibody* 
Severe HDFN Moderate HDFN HDFN in lab 





N % negative positive ? IUT/(exchange)
transfusion 
Phototherapy only ** 
c - 38 38.4 1 30 7 1          9/34*** 7/13
E - 25 25.3 1 19 5 0 3/24 2/3
c E 14 14.1 0 11 3 0 2/12 1/3
E c 6 6.1 0 5 1 1 3/5 3/3





1 1.0 0 1 0 0 0/0 0/0
c Jk
 a 3 3.0 0 3 0 0 1/3 1/1
c Jk
 b 1 1.0 0 1 0 0 0/1 0/0
c Wr
 a 1 1.0 0 1 0 0 1/1 1/1
K - 1 1.0 1 0 0 0 0/1 0/0
Jk
 a - 2 2.0 0 2 0 0 0/2 0/0
s - 1 1.0 0 1 0 0 0/1 0/0
C
 w - 5 5.1 5 0 0 0 0/4 0/0
Total   99 100 8 75 16 2 20/89 16/25
* Dominant antibody if multiple antibodies are present: antibody specificity for which the paternal antigen is 
positive and/or with  the highest estimated risk for development of HDFN.   
** Denominators for phototherapy: cases with known outcome. 
*** In one antigen-positive child only a maximum bilirubin level of 289 µmol was known, but data about 
phototherapy treatment were missing; this case was classified as moderate HDFN. 
 
Table 2. Calculation Numbers Needed to Screen (NNS) to detect late alloimmunisation in Rhc-negative 
women and subsequent disease. 
 
Screened Rhc-negative women 1/10/2011 – 1/10/2013 
N=62,096 
Numbers Needed to 
Screen 











99 0.159 (0.128-0.191) 628 
HDFN 22 0.035 (0.021-0.050) 22.22 (12.94-31.51) 2,823 
-  severe 2 0.003 (0-0.008) 2.02 (0-4.82) 31,048 
- moderate 20 0.032 (0.018-0.046) 20.20 (11.35-29.06) 3,105 
* Assumption calculation NNS: timely detection without screening programme = 0%. NNS calculated as 1/(0-
incidence in Rhc-negative women) 
Formula for calculation of the 95%-confidence intervals: p-1.96*ROOT(p*(1-p)/n), resp. p+1.96*ROOT(p*(1-
p)/n). p = proportion of alloimmunised women (0.16%) and n = the number of screened women (62,096).  
 
 





Crude OR (95%-CI) Adjusted OR* *
(95%-CI) 




































RBC transfusion  6 (13) 1 (1) 15.45 (1.80-132.4) 10.39 (1.14-94.9)
Major Surgery  18 (40)
 
21 (20) 2.64 (1.23-5.66) 2.37 (0.96-5.86)





 6 (13) 2 (2) 7.65 (1.48-39.5) 9.20 (1.16-72.9)
* Proportions determined in group with known data; missing data maximum 1. 
** Adjusted for maternal age, parity, RBC transfusion, major surgery and chorionic villus 
sampling/amniocentesis 
Goodness of fit tests showed no evidence of lack of fit (p=0.90); explained variance 36.7% (Nagelkerke 
Chisquare)  
 
